State-of-the-Art Paper
Imaging Assessment of Tricuspid Regurgitation Severity

https://doi.org/10.1016/j.jcmg.2018.07.033Get rights and content
Under an Elsevier user license
open archive

Summary

Assessing the severity of tricuspid regurgitation remains a challenging task, and although echocardiography is the test of choice, significant limitations of the current recommendations exist. Newer methods have been used in current trials of transcatheter devices and may improve our understanding of the disease process. Cardiac magnetic resonance imaging and computed tomography angiography may play significant roles as adjunctive imaging modalities. This paper reviews the imaging modalities currently used to quantify tricuspid regurgitation severity.

Key Words

cardiac magnetic resonance
computed tomography angiography
echocardiography

Abbreviations and Acronyms

2D
2-dimensional
AROA
anatomic regurgitant orifice area
CMR
cardiac magnetic resonance imaging
CTA
computed tomography angiography
CW
continuous wave
EROA
effective regurgitant orifice area
PC
phase-contrast
PISA
proximal isovelocity surface area
PW
pulsed wave
RA
right atrium
TR
tricuspid regurgitation
va
aliasing velocity
Vmax
maximum tricuspid regurgitation velocity
VC
vena contracta
VCA
vena contracta area

Cited by (0)

Dr. Hahn is the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for which she receives no direct industry compensation; and has received personal fees from Abbott Vascular, Boston Scientific, Bayliss, Navigate, Philips Healthcare, and Siemens Healthineers. Dr. Thomas is a consultant for and receives honoraria from Edwards Lifesciences, Abbott, GE Healthcare, and Bay Labs; and his spouse is an employee of Bay Labs. Dr. Khalique is a member of the Speakers Bureau for Edwards Lifesciences; and is a consultant for Cephea Valves and Jenavalve. Dr. Cavalcante is a consultant for Medtronic and Mitralign; and has received research support from Medtronic, Siemens and Circle CVI. Dr. Praz is a consultant for Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.